{"id":876172,"date":"2025-08-14T21:09:20","date_gmt":"2025-08-15T01:09:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/"},"modified":"2025-08-14T21:09:20","modified_gmt":"2025-08-15T01:09:20","slug":"24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/","title":{"rendered":"24\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\/2 Trial Readout Expected in 2H 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        <strong><br \/>\n          <em>Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>24\/7 Market News Issues Corrected Information on Previously issued Press Release with same title<\/strong>\n      <\/p>\n<p>DENVER, Aug.  14, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DiazhYmLoOb8Jb4CqLHpwKA64TksZaRUdXBltGwMZtJOw8VUFUV98dDqyfCMBkws0TsBid_Jz0iJuDF_jZjUxhACDChtme45gNH_Nqe7e3KAKYODkvMOLaRz2GFp4EFC\" rel=\"nofollow\" target=\"_blank\"><u>247marketnews.com<\/u><\/a>, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways.<\/p>\n<p>2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity.<\/p>\n<p>\n        <strong>Upcoming Catalysts: Anticipated Trial Results in 2H 2025<\/strong>\n      <\/p>\n<p>\n        <strong>1B\/2 Trial \u2013 Ovarian Clear Cell Carcinoma (OCCC)<\/strong>\n      <\/p>\n<p>Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5\u201310% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality.<\/p>\n<p>The Phase 1B\/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100\u2019s synergistic enhancement of immune checkpoint blockade.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Status:<\/strong> Enrolled, with interim safety completed<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Upcoming Milestone:<\/strong> Preliminary safety and efficacy data expected Q4 2025<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Potential Market Impact:<\/strong> Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies<\/li>\n<\/ul>\n<p>\n        <strong>1B\/2 Trial \u2013 Advanced Soft Tissue Sarcoma (STS)<\/strong>\n      <\/p>\n<p>Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains poor.<br \/>LIXTE\u2019s Phase 1B\/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Status:<\/strong> Dose escalation completed.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Upcoming Milestone:<\/strong> Safety report Q4 2025<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Potential Market Impact:<\/strong> The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need<\/li>\n<\/ul>\n<p>\n        <strong>1B Trial \u2013 Metastatic Microsatellite Stable (MSS) Colon Cancer<\/strong>\n      <\/p>\n<p>MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors.<\/p>\n<p>LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Status:<\/strong> Trial open, first patients recruited<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Potential Market Impact:<\/strong> The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases<\/li>\n<\/ul>\n<p>\n        <strong>Platform Potential and Market Opportunity<\/strong>\n      <\/p>\n<p>LIXTE\u2019s strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform\u2019s potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Strong IP Position<\/strong>: Multiple issued and pending patents covering composition, methods of use, and combinations<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Pipeline Expansion<\/strong>: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Partnership Potential<\/strong>: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities<\/li>\n<\/ul>\n<p>Contact <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ty9gxPNh-TdGA21ywOt8c0_YMuiO0s355lyGyBp2dZLNPT7G0BLzOV0o6LPhSyZZ93-45BbEqblgfSYTcelm2dco4_caLixc105o3eeYszTDkvntUtc8trtWJnnOqjXt\" rel=\"nofollow\" target=\"_blank\"><u>sales@247marketnews.com<\/u><\/a> for Analyst Report coverage and other investor\/public relations services.<\/p>\n<p>\n        <strong>About LIXTE Biotechnology Holdings, Inc.<\/strong>\n      <\/p>\n<p>LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company\u2019s lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.<\/p>\n<p>More information can be found at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q8uW0Ye_T_9C8uTxoubsTYQdRIJQlZ0rj2XsZKUq9LJc0Ob1QGCi1qoYqjb_PgxQIJ8ywsYj4NR_WLJPWV5c6Q==\" rel=\"nofollow\" target=\"_blank\">www.lixte.com<\/a><\/p>\n<p>\n        <strong>24\/7 MARKET NEWS, INC Disclaimer<\/strong><br \/>\n        <br \/>Please go to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9iQMmNBxxPXp8WP_LuNRVBm2xPwfvQgHJwa-dcOb3_cs9HnNVpuwUBNhAzzZY4fAgVm_3ggrofwhJnidlQ95OUZV7lEsD9V7g3zIcFOxhsQeOi-lRgoSaHBH390WRpDh1B2O68M0SzCvzoZrqGCcPINhcAqFmtd3fMFj8AjgY04=\" rel=\"nofollow\" target=\"_blank\">https:\/\/247marketnews.com\/lixte-biotechnology\/<\/a> for further LIXT information and 247marketnews.com LIXT disclosure information.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company&#8217;s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;estimates,&#8221; &#8220;aims,&#8221; &#8220;believes,&#8221; &#8220;hopes,&#8221; &#8220;potential&#8221; or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company&#8217;s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company&#8217;s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEwOSM3MTAwOTU0IzUwMDE1MDUxMw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjExNzMzNjUtNzBhZS00YmFiLThiZDctOWM0OGU4ZmRmNDk1LTUwMDE1MDUxMy0yMDI1LTA4LTE1LWVu\/tiny\/LIXTE-Biotechnology-Holdings-a.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>CONTACT:\r\n24\/7 Market News\r\nEditor@247marketnews.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24\/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) &#8212; 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;24\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\/2 Trial Readout Expected in 2H 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-876172","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>24\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\/2 Trial Readout Expected in 2H 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"24\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\/2 Trial Readout Expected in 2H 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24\/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) &#8212; 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling &hellip; Continue reading &quot;24\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\/2 Trial Readout Expected in 2H 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-15T01:09:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEwOSM3MTAwOTU0IzUwMDE1MDUxMw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"24\\\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\\\/2 Trial Readout Expected in 2H 2025\",\"datePublished\":\"2025-08-15T01:09:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\\\/\"},\"wordCount\":823,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMzEwOSM3MTAwOTU0IzUwMDE1MDUxMw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\\\/\",\"name\":\"24\\\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\\\/2 Trial Readout Expected in 2H 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMzEwOSM3MTAwOTU0IzUwMDE1MDUxMw==\",\"datePublished\":\"2025-08-15T01:09:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMzEwOSM3MTAwOTU0IzUwMDE1MDUxMw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMzEwOSM3MTAwOTU0IzUwMDE1MDUxMw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"24\\\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\\\/2 Trial Readout Expected in 2H 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"24\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\/2 Trial Readout Expected in 2H 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/","og_locale":"en_US","og_type":"article","og_title":"24\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\/2 Trial Readout Expected in 2H 2025 - Market Newsdesk","og_description":"Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24\/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) &#8212; 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling &hellip; Continue reading \"24\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\/2 Trial Readout Expected in 2H 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-15T01:09:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEwOSM3MTAwOTU0IzUwMDE1MDUxMw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"24\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\/2 Trial Readout Expected in 2H 2025","datePublished":"2025-08-15T01:09:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/"},"wordCount":823,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEwOSM3MTAwOTU0IzUwMDE1MDUxMw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/","name":"24\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\/2 Trial Readout Expected in 2H 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEwOSM3MTAwOTU0IzUwMDE1MDUxMw==","datePublished":"2025-08-15T01:09:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEwOSM3MTAwOTU0IzUwMDE1MDUxMw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEwOSM3MTAwOTU0IzUwMDE1MDUxMw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"24\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\/2 Trial Readout Expected in 2H 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=876172"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876172\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=876172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=876172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=876172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}